Previous 10 | Next 10 |
Dynavax Technologies (NASDAQ: DVAX ) +41% as COVID-19 vaccine trial could start as soon as July. More news on: Dynavax Technologies Corporation, Arbutus Biopharma Corporation, cbdMD, Inc., Stocks on the move, , Read more ...
Genocea Biosciences (NASDAQ: GNCA ) inks a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. ( OTCPK:SGIOY ) to develop a novel herpes simplex virus type 2 (HSV-2) vaccine. More news on: Genocea Biosciences, Inc., Shionogi & Co., Ltd., Healt...
CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shion...
Seven out of eight patients treated on Part A of the study are without disease progression at one-year median follow-up ATLAS™-identified neoantigens generate broad, sustained T cell responses starting after only 4 weeks and lasting for up to 6 months after the last vaccination ...
Thinly traded nano cap Genocea Biosciences (NASDAQ: GNCA ) is up 16% premarket on average volume on the heels of a key opinion leader (KOL) symposium yesterday focused on GEN-011, its neoantigen cell therapy that, it says, improves on the limitations of tumor-infiltrating lymph...
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium today with Dr. Eric Tran, Assistant Member at the Earle A. Chiles Research Institute in ...
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T...
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T ce...
Genocea Biosciences, Inc. (GNCA) Q1 2020 Earnings Conference Call April 30, 2020, 08:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Chip Clark - President and CEO Diantha Duvall - CFO Tom Davis - Chief Medical Officer Jessica Flechtner - Chief S...
Genocea Biosciences (NASDAQ: GNCA ): Q1 GAAP EPS of -$0.46 misses by $0.11 . More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc. Website: